| Schneider, Eric |
MAGNIFY, NCT05893537: Study to Evaluate the Efficacy and Safety of Oral CT1812 in Participants with Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (AMD). |
|
|
| Recruiting | 2 | 246 | US | Active Comparator CT1812, Placebo Comparator | Cognition Therapeutics | Age-Related Macular Degeneration | 07/27 | 08/27 | | |
NCT05345769: Safety and Efficacy of AM712 in Patients with NAMD |
|
|
| Completed | 1 | 21 | US | AM712(ASKG712) | AffaMed Therapeutics Limited | Neovascular Age-related Macular Degeneration | 11/24 | 11/24 | | |
NCT05202587: The Evaluation of the Agreement Between the NVHO in the Automatic Fluid Quantification and Cirrus OCT |
|
|
| Completed | N/A | 386 | US | | Notal Vision Inc. | Neovascular Age-related Macular Degeneration | 01/23 | 01/23 | | |
| Busbee, Brandon G |
SIGLEC, NCT05839041: A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) |
|
|
| Active, not recruiting | 2 | 300 | US | AVD-104, Avacincaptad | Aviceda Therapeutics, Inc. | Geographic Atrophy of the Macula, Macular Degeneration | 09/25 | 09/26 | | |
| Aaberg, Thomas |
NCT06397131: A Study to Determine the Safety and Efficacy of NT-501 With MHFM |
|
|
| Not yet recruiting | 3 | 13 | US | NT-501 CNTF Implant | Neurotech Pharmaceuticals | Macular Telangiectasia Type 2 | 04/26 | 07/26 | | |
AL, NCT05844982: Intravitreal Faricimab Injections or Fluocinolone Acetonide (0.19 Mg) Intravitreal Implants Vs Observation for Prevention of VA Loss Due to Radiation Retinopathy |
|
|
| Recruiting | 3 | 600 | US | Faricimab, fluocinolone acetonide | Jaeb Center for Health Research, National Eye Institute (NEI), National Institutes of Health (NIH), Alimera Sciences, Genentech, Inc. | Radiation Retinopathy, Visual Impairment | 12/29 | 12/29 | | |
| Recruiting | 3 | 560 | US | Fenofibrate, Placebo | Jaeb Center for Health Research, National Institutes of Health (NIH), National Eye Institute (NEI), Juvenile Diabetes Research Foundation, Roche Pharma AG, The Leona M. and Harry B. Helmsley Charitable Trust | Diabetic Retinopathy | 04/29 | 04/29 | | |
SIGLEC, NCT05839041: A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) |
|
|
| Active, not recruiting | 2 | 300 | US | AVD-104, Avacincaptad | Aviceda Therapeutics, Inc. | Geographic Atrophy of the Macula, Macular Degeneration | 09/25 | 09/26 | | |
| Sheth, Veeral |
INSITE-DME, NCT05610319: Treat & Extend Versus Fixed Dosing with Faricimab for Management of Diabetic Macular Edema: a Pragmatic, Multi-center, Open-label, Randomized, Controlled Trial |
|
|
| Active, not recruiting | 4 | 446 | Europe, Canada, US, RoW | Faricimab | McMaster University, Hoffmann-La Roche | Diabetic Macular Edema | 12/26 | 12/26 | | |
| Recruiting | 2/3 | 497 | US | Dexamethasone ophthalmic suspension (OCS-01), Dexamethasone, Vehicle, Placebo | Oculis, ICON plc | Diabetic Macular Edema | 06/26 | 06/26 | | |
SIGLEC, NCT05839041: A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) |
|
|
| Active, not recruiting | 2 | 300 | US | AVD-104, Avacincaptad | Aviceda Therapeutics, Inc. | Geographic Atrophy of the Macula, Macular Degeneration | 09/25 | 09/26 | | |
| Recruiting | 1/2 | 215 | US | 4D-150 IVT, Aflibercept IVT | 4D Molecular Therapeutics | Neovascular (Wet) Age-Related Macular Degeneration | 11/25 | 11/26 | | |
NCT05643118: Evaluation of OLX10212 in Patients With Neovascular Age-related Macular Degeneration |
|
|
| Recruiting | 1 | 42 | US | OLX10212 is a cell penetrating asymmetric small interference RNA (cp-asiRNA), OLX10212 | Olix Pharmaceuticals, Inc., Trial Runners, LLC | Neovascular Age-related Macular Degeneration | 11/24 | 12/24 | | |
| Active, not recruiting | N/A | 95 | US | i-Lumen(TM) AMD, i-Lumen(TM) AMD Sham | i-Lumen Scientific, Inc. | Age-Related Macular Degeneration, Dry Age-related Macular Degeneration, Nonexudative Age-related Macular Degeneration | 06/25 | 06/25 | | |
| Kirby, BreAnne |
Tejas, NCT05387837: Safety, Tolerability and PK of Subcutaneous D-4517.2 in Subjects With Wet AMD or DME |
|
|
| Active, not recruiting | 2 | 50 | US | D-4517.2, aflibercept | Ashvattha Therapeutics, Inc. | Neovascular Age-related Macular Degeneration, Diabetic Macular Edema | 11/24 | 12/24 | | |
| Recruiting | 1/2 | 215 | US | 4D-150 IVT, Aflibercept IVT | 4D Molecular Therapeutics | Neovascular (Wet) Age-Related Macular Degeneration | 11/25 | 11/26 | | |
NCT05643118: Evaluation of OLX10212 in Patients With Neovascular Age-related Macular Degeneration |
|
|
| Recruiting | 1 | 42 | US | OLX10212 is a cell penetrating asymmetric small interference RNA (cp-asiRNA), OLX10212 | Olix Pharmaceuticals, Inc., Trial Runners, LLC | Neovascular Age-related Macular Degeneration | 11/24 | 12/24 | | |
| Active, not recruiting | N/A | 11 | US | episcleral brachytherapy, Strontium 90 | Salutaris Medical Devices, Inc. | Macular Degeneration, Choroidal Neovascularization | 05/23 | 05/25 | | |
| Active, not recruiting | N/A | 95 | US | i-Lumen(TM) AMD, i-Lumen(TM) AMD Sham | i-Lumen Scientific, Inc. | Age-Related Macular Degeneration, Dry Age-related Macular Degeneration, Nonexudative Age-related Macular Degeneration | 06/25 | 06/25 | | |
| Reichstein, David |
AL, NCT05844982: Intravitreal Faricimab Injections or Fluocinolone Acetonide (0.19 Mg) Intravitreal Implants Vs Observation for Prevention of VA Loss Due to Radiation Retinopathy |
|
|
| Recruiting | 3 | 600 | US | Faricimab, fluocinolone acetonide | Jaeb Center for Health Research, National Eye Institute (NEI), National Institutes of Health (NIH), Alimera Sciences, Genentech, Inc. | Radiation Retinopathy, Visual Impairment | 12/29 | 12/29 | | |
NCT05266430: Prospective Group-Matched Study With Belzupacap Sarotalocan (Bel-sar; AU-011) or Plaque Radiotherapy for Primary Indeterminate Lesions or Choroidal Melanoma (IL/ CM) |
|
|
| Terminated | N/A | 2 | US | Standard of Care, AU-011, belzupacap sarotalocan, bel-sar | Aura Biosciences | Choroidal Melanoma, Indeterminate Lesions | 02/23 | 04/23 | | |
| Walden, Lisa |
NCT04417530: Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma |
|
|
| Completed | 2 | 22 | US | AU-011, Suprachoroidal Microinjector, PDT Laser | Aura Biosciences | Uveal Melanoma, Ocular Melanoma, Choroidal Melanoma | 04/24 | 04/24 | | |
| Active, not recruiting | 2 | 179 | US | Faricimab | Greater Houston Retina Research, Genentech, Inc. | Non-Proliferative Diabetic Retinopathy | 03/26 | 04/26 | | |
| Recruiting | 1/2 | 215 | US | 4D-150 IVT, Aflibercept IVT | 4D Molecular Therapeutics | Neovascular (Wet) Age-Related Macular Degeneration | 11/25 | 11/26 | | |
NCT05202587: The Evaluation of the Agreement Between the NVHO in the Automatic Fluid Quantification and Cirrus OCT |
|
|
| Completed | N/A | 386 | US | | Notal Vision Inc. | Neovascular Age-related Macular Degeneration | 01/23 | 01/23 | | |
NCT05266430: Prospective Group-Matched Study With Belzupacap Sarotalocan (Bel-sar; AU-011) or Plaque Radiotherapy for Primary Indeterminate Lesions or Choroidal Melanoma (IL/ CM) |
|
|
| Terminated | N/A | 2 | US | Standard of Care, AU-011, belzupacap sarotalocan, bel-sar | Aura Biosciences | Choroidal Melanoma, Indeterminate Lesions | 02/23 | 04/23 | | |
NCT03941379: A Registry of Subjects With Primary Indeterminate Lesions or Choroidal Melanoma |
|
|
| Recruiting | N/A | 500 | US | | Aura Biosciences | Choroidal Melanoma, Indeterminate Lesions of Eye | 12/29 | 12/29 | | |
| Awh, Carl |
| Active, not recruiting | 2 | 179 | US | Faricimab | Greater Houston Retina Research, Genentech, Inc. | Non-Proliferative Diabetic Retinopathy | 03/26 | 04/26 | | |
| Recruiting | 1/2 | 215 | US | 4D-150 IVT, Aflibercept IVT | 4D Molecular Therapeutics | Neovascular (Wet) Age-Related Macular Degeneration | 11/25 | 11/26 | | |
| Thomas, Akshay |
NCT05322070: Fluocinolone Acetonide Intravitreal Implant 0.18 mg in the Treatment of Chronic Non-Infectious Posterior Segment Uveitis |
|
|
| Active, not recruiting | 4 | 125 | US | Fluocinolone Acetonide Intravitreal Implant 0.18 mg, YUTIQ 0.18 mg | Alimera Sciences, CBCC Global Research | Uveitis, Posterior | 11/25 | 11/25 | | |
| Vallejo, Cindy |
INSITE-DME, NCT05610319: Treat & Extend Versus Fixed Dosing with Faricimab for Management of Diabetic Macular Edema: a Pragmatic, Multi-center, Open-label, Randomized, Controlled Trial |
|
|
| Active, not recruiting | 4 | 446 | Europe, Canada, US, RoW | Faricimab | McMaster University, Hoffmann-La Roche | Diabetic Macular Edema | 12/26 | 12/26 | | |
ReNEW, NCT06373731: Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD) |
|
|
| Recruiting | 3 | 360 | Europe, US, RoW | Elamipretide, Elamipretide HCL, Placebo | Stealth BioTherapeutics Inc. | Age Related Macular Degeneration (ARMD) | 08/26 | 08/27 | | |
| Recruiting | 1/2 | 215 | US | 4D-150 IVT, Aflibercept IVT | 4D Molecular Therapeutics | Neovascular (Wet) Age-Related Macular Degeneration | 11/25 | 11/26 | | |
| Patel, Nilam |
SIGLEC, NCT05839041: A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) |
|
|
| Active, not recruiting | 2 | 300 | US | AVD-104, Avacincaptad | Aviceda Therapeutics, Inc. | Geographic Atrophy of the Macula, Macular Degeneration | 09/25 | 09/26 | | |
| Montgomery, Sara |
SIGLEC, NCT05839041: A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) |
|
|
| Active, not recruiting | 2 | 300 | US | AVD-104, Avacincaptad | Aviceda Therapeutics, Inc. | Geographic Atrophy of the Macula, Macular Degeneration | 09/25 | 09/26 | | |
